The no-reflow phenomenon in the young and in the elderly

International Journal of Cardiology

Volumn 222, Issue , 2016, Pages 1122-1128

  Cenko, Edina ^a   Ricci, Beatrice ^a   Kedev, Sasko ^b   Kalpak, Oliver ^b   Câlmâc, Lucian ^c   Vasiljevic, Zorana ^d   Knežević, Božidarka ^e   Dilic, Mirza ^f   Miličić, Davor ^g   Manfrini, Olivia ^a   Koller, Akos ^h   Dorobantu, Maria ^c,i   Badimon, Lina ^j   Bugiardini, Raffaele ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b SS CYRIL AND METHODIUS UNIVERSITY   (Macedonia)

^c Clinic Emergency Hospital Bucharest   (Romania)

^d UNIVERSITY OF BELGRADE   (Serbia)

^e UNIVERSITY OF MONTENEGRO   (Montenegro)

^f UNIVERSITY OF SARAJEVO   (Bosnia and Herzegovina)

^g KBC Zagreb   (Croatia)

^h UNIVERSITY OF PHYSICAL EDUCATION   (Hungary)

ⁱ CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^j UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

more..

Author keywords

Acute coronary syndromes; Mortality; No reflow; Percutaneous coronary intervention; Therapy

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; ENOXAPARIN; HEPARIN;

ACUTE CORONARY SYNDROME; ADULT; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; FEMALE; HEMODYNAMIC PARAMETERS; HOSPITAL MORTALITY; HUMAN; HYPERCHOLESTEROLEMIA; INCIDENCE; LENGTH OF STAY; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NO REFLOW PHENOMENON; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; THROMBOLYSIS IN MYOCARDIAL INFARCTION BLOOD FLOW GRADE; ADVERSE EFFECTS; CLINICAL TRIAL; CORONARY ANGIOGRAPHY; CORONARY BLOOD VESSEL; DIAGNOSTIC IMAGING; EUROPE; FOLLOW UP; MIDDLE AGED; MULTICENTER STUDY; MYOCARDIAL INFARCTION; NO-REFLOW PHENOMENON; REGISTER; RETROSPECTIVE STUDY; RISK FACTOR; SURVIVAL RATE; TIME FACTOR; TRENDS;

CORONARY ANGIOGRAPHY; CORONARY VESSELS; EUROPE; FEMALE; FOLLOW-UP STUDIES; HOSPITAL MORTALITY; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; NO-REFLOW PHENOMENON; PERCUTANEOUS CORONARY INTERVENTION; REGISTRIES; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; TIME FACTORS;

EID: 84994275146     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2016.07.209     Document Type: Article

References (49)

1. [1] Kloner, R.A., Ganote, C.E., Jennings, R.B., The “no-reflow” phenomenon after temporary coronary occlusion in the dog. J. Clin. Invest. 54 (1974), 1496–1508.
2. [2] Abbo, K.M., Dooris, M., Glazier, S., et al. Features and outcome of no-reflow after percutaneous coronary intervention. Am. J. Cardiol. 75 (1995), 778–782.
3. [3] Harrison, R.W., Aggarwal, A., Ou, F.S., et al. Incidence and outcomes of no-reflow phenomenon during percutaneous coronary intervention among patients with acute myocardial infarction. Am. J. Cardiol. 111 (2013), 178–184.
4. [4] Ndrepepa, G., Tiroch, K., Fusaro, M., et al. 5-year prognostic value of no-reflow phenomenon after percutaneous coronary intervention in patients with acute myocardial infarction. J. Am. Coll. Cardiol. 55 (2010), 2383–2389.
5. [5] Wu, X., Mintz, G.S., Xu, K., et al. The relationship between attenuated plaque identified by intravascular ultrasound and no-reflow after stenting in acute myocardial infarction: the HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trial. JACC Cardiovasc. Interv. 4 (2011), 495–502.
6. [6] Resnic, F.S., Wainstein, M., Lee, M.K., et al. No-reflow is an independent predictor of death and myocardial infarction after percutaneous coronary intervention. Am. Heart J. 145 (2003), 42–46.
7. [7] Kaplan, B.M., Benzuly, K.H., Kinn, J.W., et al. Treatment of no-reflow in degenerated saphenous vein graft interventions: comparison of intracoronary verapamil and nitroglycerin. Catheter. Cardiovasc. Diagn. 39 (1996), 113–118.
8. [8] Jaffe, R., Charron, T., Puley, G., Dick, A., Strauss, B.H., Microvascular obstruction and the no-reflow phenomenon after percutaneous coronary intervention. Circulation 117 (2008), 3152–3156.
9. [9] Manfrini, O., Morgagni, G., Pizzi, C., Fontana, F., Bugiardini, R., Changes in autonomic nervous system activity: spontaneous versus balloon-induced myocardial ischaemia. Eur. Heart J. 25 (2004), 1502–1508.
10. [10] Manfrini, O., Pizzi, C., Viecca, M., Bugiardini, R., Abnormalities of cardiac autonomic nervous activity correlate with expansive coronary artery remodeling. Atherosclerosis 197 (2008), 183–189.
11. [11] Pries, A.R., Badimon, L., Bugiardini, R., et al. Coronary vascular regulation, remodelling, and collateralization: mechanisms and clinical implications on behalf of the working group on coronary pathophysiology and microcirculation. Eur. Heart J. 36 (2015), 3134–3146.
12. [12] Gregorini, L., Marco, J., Kozàkovà, M., et al. Alpha-adrenergic blockade improves recovery of myocardial perfusion and function after coronary stenting in patients with acute myocardial infarction. Circulation 99 (1999), 482–490.
13. [13] Bugiardini, R., Badimon, L., Manfrini, O., Rationale and design of the ISACS-TC (International Survey of Acute Coronary Syndromes in Transitional Countries) project. Eur. Heart J. Suppl. 16 (2014), A1–A6.
14. [14] Bugiardini, R., Cenko, E., Ricci, B., et al. Comparison of early versus delayed oral β blockers in acute coronary syndromes and effect on outcomes. Am. J. Cardiol. 117 (2016), 760–767.
15. [15] Cenko, E., Ricci, B., Kedev, S., et al. Reperfusion therapy for ST-elevation acute myocardial infarction in Eastern Europe: the ISACS-TC registry. Eur. Heart J. Qual. Care Clin. Outcomes 2 (2016), 45–51.
16. [16] Bugiardini, R., Dorobantu, M., Vasiljevic, Z., et al. Unfractionated heparin-clopidogrel combination in ST-elevation myocardial infarction not receiving reperfusion therapy. Atherosclerosis 241 (2015), 151–156.
17. [17] Bugiardini, R., Manfrini, O., Majstorovic Stakic, M., et al. Exploring in-hospital death from myocardial infarction in Eastern Europe; from the International Registry of Acute Coronary Syndromes in Transitional Countries (ISACS-TC); on the behalf of the Working Group on Coronary Pathophysiology & Microcirculation of the European Society of Cardiology. Curr. Vasc. Pharmacol. 12 (2014), 903–909.
18. [18] Dorobantu, M., Tautu, O.-F., Fruntelata, A., et al. Hypertension and acute coronary syndromes in Romania: data from the ISACS-TC registry. Eur. Heart J. Suppl. 16 (2014), A20–A27.
19. [19] Vasiljevic, Z., Krljanac, G., Davidovic, G., et al. Gender differences in case fatality rates of acute myocardial infarction in Serbia. Eur. Heart J. Suppl. 16 (2014), A48–A55.
20. [20] Manfrini, O., Dorobantu, M., Vasiljevic, Z., et al. Acute coronary syndrome in octogenarian patients: results from the international registry of acute coronary syndromes in transitional countries (ISACS-TC) registry. Eur. Heart J. Suppl., 16, 2014, A87-A9.
21. [21] Thygesen, K., Alpert, J.S., Jaffe, A.S., Simoons, M.L., Chaitman, B.R., White, H.D., Third universal definition of myocardial infarction. Nat. Rev. Cardiol. 9 (2012), 620–633.
22. [22] Mehran, R., Rao, S.V., Bhatt, D.L., et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation 123 (2011), 2736–2747.
23. [23] Yellon, D.M., Hausenloy, D.J., Myocardial reperfusion injury. N. Engl. J. Med. 357 (2007), 1121–1135.
24. [24] Matsumura, K., Jeremy, R.W., Schaper, J., Becker, L.C., Progression of myocardial necrosis during reperfusion of ischemic myocardium. Circulation 97 (1998), 795–804.
25. [25] Gressin, V., Louvard, Y., Pezzano, M., Lardoux, H., Holter recording of ventricular arrhythmias during intravenous thrombolysis for acute myocardial infarction. Am. J. Cardiol. 69 (1992), 152–159.
26. [26] Heper, G., Korkmaz, M.E., Kilic, A., Reperfusion arrhythmias: are they only a marker of epicardial reperfusion or continuing myocardial ischemia after acute myocardial infarction?. Angiology 58 (2008), 663–670.
27. [27] Budaj, A., Flasinska, K., Gore, J.M., et al. Magnitude of and risk factors for in-hospital and postdischarge stroke in patients with acute coronary syndromes: findings from a Global Registry of Acute Coronary Events. Circulation 111 (2005), 3242–3247.
28. [28] Guptill, J.T., Mehta, R.H., Armstrong, P.W., et al. Stroke after primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction: timing, characteristics, and clinical outcomes. Circ. Cardiovasc. Interv. 6 (2013), 176–183.
29. [29] Henriques, J.P., Zijlstra, F., Ottervanger, J.P., et al. Incidence and clinical significance of distal embolization during primary angioplasty for acute myocardial infarction. Eur. Heart J. 23 (2002), 1112–1117.
30. [30] Claessen, B.E., Kikkert, W.J., Engstrom, A.E., et al. Primary percutaneous coronary intervention for ST elevation myocardial infarction in octogenarians: trends and outcomes. Heart 96 (2010), 843–847.
31. [31] Moonen, L.A., van ‘t Veer, M., Pijls, N.H., Procedural and long-term outcome of primary percutaneous coronary intervention in octogenarians. Neth. Heart J. 18 (2010), 129–134.
32. [32] Sakai, K., Nagayama, S., Ihara, K., et al. Primary percutaneous coronary intervention for acute myocardial infarction in the elderly aged ≥ 75 years. Catheter. Cardiovasc. Interv. 79 (2012), 50–56.
33. [33] Turschner, O., D'hooge, J., Dommke, C., et al. The sequential changes in myocardial thickness and thickening which occur during acute transmural infarction, infarct reperfusion and the resultant expression of reperfusion injury. Eur. Heart J. 25 (2004), 794–803.
34. [34] Goodwill, A.G., Stapleton, P.A., James, M.E., D'Audiffret, A.C., Frisbee, J.C., Increased arachidonic acid-induced thromboxane generation impairs skeletal muscle arteriolar dilation with genetic dyslipidemia. Microcirculation 15 (2008), 621–631.
35. [35] Iwakura, K., Ito, H., Kawano, S., et al. Chronic pre-treatment of statins is associated with the reduction of the no-reflow phenomenon in the patients with reperfused acute myocardial infarction. Eur. Heart J. 27 (2006), 534–539.
36. [36] Winchester, D.E., Wen, X., Xie, L., Bavry, A.A., Evidence of pre-procedural statin therapy a meta-analysis of randomized trials. J. Am. Coll. Cardiol. 56 (2010), 1099–1109.
37. [37] Manfrini, O., Pizzi, C., Morgagni, G., Fontana, F., Bugiardini, R., Effect of pravastatin on myocardial perfusion after percutaneous transluminal coronary angioplasty. Am. J. Cardiol. 93 (2004), 1391–1393 (A6).
38. [38] Bugiardini, R., Pozzati, A., Ottani, F., Morgagni, G.L., Puddu, P., Vasotonic angina: a spectrum of ischemic syndromes involving functional abnormalities of the epicardial and microvascular coronary circulation. J. Am. Coll. Cardiol. 22 (1993), 417–425.
39. [39] Manfrini, O., Cenko, E., Verna, E., Salerno Uriarte, J.A., Bugiardini, R., Endothelial dysfunction versus early atherosclerosis: a study with high resolution imaging. Int. J. Cardiol. 168 (2013), 1714–1716.
40. [40] Yip, H.K., Chen, M.C., Chang, H.W., et al. Angiographic morphologic features of infarct-related arteries and timely reperfusion in acute myocardial infarction: predictors of slow-flow and no-reflow phenomenon. Chest 122 (2002), 1322–1332.
41. [41] Jung, J.H., Min, P.K., Lee, S.H., et al. Clopidogrel pretreatment before primary percutaneous coronary stenting in patients with acute ST-segment elevation myocardial infarction: comparison of high loading dose (600 mg) versus low loading dose (300 mg). Coron. Artery Dis. 20 (2009), 150–154.
42. [42] Patti, G., Colonna, G., Pasceri, V., Pepe, L.L., Montinaro, A., Di Sciascio, G., Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (antiplatelet therapy for reduction of MYocardial damage during angioplasty) study. Circulation 111 (2005), 2099–2106.
43. [43] Zalewski, J., Undas, A., Godlewski, J., Stepien, E., Zmudka, K., No-reflow phenomenon after acute myocardial infarction is associated with reduced clot permeability and susceptibility to lysis. Arterioscler. Thromb. Vasc. Biol. 27 (2007), 2258–2265.
44. [44] Cairns, J.A., Theroux, P., Lewis, H.D. Jr., Ezekowitz, M., Meade, T.W., Antithrombotic agents in coronary artery disease. Chest 119 (2001), 228S–252S.
45. [45] Farrehi, P.M., Ozaki, C.K., Carmeliet, P., Fay, W.P., Regulation of arterial thrombolysis by plasminogen activator inhibitor-1 in mice. Circulation 97 (1998), 1002–1008.
46. [46] Montalescot, G., Zeymer, U., Silvain, J., et al. Intravenous enoxaparin or unfractionated heparin in primary percutaneous coronary intervention for ST-elevation myocardial infarction: the international randomised open-label ATOLL trial. Lancet 378 (2011), 693–703.
47. [47] Shewan, L.G., Coats, A.J., Adherence to ethical standards in publishing scientific articles: a statement from the International Journal of Cardiology. Int. J. Cardiol. 161 (2012), 124–125.
48. [48] Alfonso, F., Timmis, A., Pinto, F.J., et al. Conflict of interest policies and disclosure requirements among European Society of Cardiology National Cardiovascular Journals. Eur. Heart J. 33 (2012), 587–594.
49. [49] ESC Board, Relations between professional medical associations and the health-care industry, concerning scientific communication and continuing medical education: a policy statement from the European Society of Cardiology. Eur. Heart J. 33 (2012), 666–674.